Home › Research › Treatments
Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type
Dysken MW, Mendels J, LeWitt P, Reisberg B, Pomara N, Wood J, Skare S, Fakouhi JD et al.. Journal of the American Geriatrics Society, 1992-05-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Objective Milacemide, a MAO-B inhibitor that is also a prodrug for glycine, was tested as a treatment for senile dementia of the Alzheimer type (SDAT) because of its potential for enhancing cognition in animal models of impaired learning and memory. Design Double-blind, placebo-controlled, randomized clinical trial. Setting Sixteen study sites, both university-affiliated and private. Patients A total of 228 outpatients (116 men and 112 women) with SDAT, ranging in age from 49-93 years. Intervention 1200 mg/day milacemide treatment for 1 month (113 patients received milacemide, and 115 patients received placebo). Main outcome measures Alzheimer's Disease Assessment Scale and the Mini-Mental State Examination. Results Milacemide-treated SDAT patients did not show significant improvement in any of the outcome measures used. Significant elevations in liver enzymes in four subjects were of sufficient magnitude to necessitate withdrawal from the study. Conclusions Milacemide does not appear to be an effective treatment in enhancing cognition in SDAT patients.
What this study adds
Evidence grade: High
This is a trial of 113 participants. In this trial of 228 patients with senile dementia of the Alzheimer type, milacemide produced no significant improvement on any outcome measure, and four subjects had liver enzyme elevations large enough to require withdrawal. The authors conclude milacemide does not appear to be an effective treatment for enhancing cognition in these patients.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Dysken, M. W., Mendels, J., LeWitt, P., Reisberg, B., Pomara, N., Wood, J., et al. (1992). Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type. Journal of the American Geriatrics Society. https://doi.org/10.1111/j.1532-5415.1992.tb02019.x
Vancouver
Dysken MW, Mendels J, LeWitt P, Reisberg B, Pomara N, Wood J, et al. Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type. Journal of the American Geriatrics Society. 1992. doi:10.1111/j.1532-5415.1992.tb02019.x. PMID: 1634705.
BibTeX
@article{dysken1992-1634705,
author = {Dysken, M. W. and Mendels, J. and LeWitt, P. and Reisberg, B. and Pomara, N. and Wood, J. and Skare, S. and Fakouhi, J. D. and others},
title = {{Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type}},
journal = {Journal of the American Geriatrics Society},
year = {1992},
doi = {10.1111/j.1532-5415.1992.tb02019.x},
pmid = {1634705},
url = {https://doi.org/10.1111/j.1532-5415.1992.tb02019.x}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results Milacemide-treated SDAT patients did not show significant improvement in any of the outcome measures used.
- Significant elevations in liver enzymes in four subjects were of sufficient magnitude to necessitate withdrawal from the study.
Why it matters
In this trial of 228 patients with senile dementia of the Alzheimer type, milacemide produced no significant improvement on any outcome measure, and four subjects had liver enzyme elevations large enough to require withdrawal. The authors conclude milacemide does not appear to be an effective treatment for enhancing cognition in these patients.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants113
- Evidence strengthHigh
How this study scored 60/100
Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of the American Geriatrics Society) |
| Journal's citation record | 3 / 4 | Journal of the American Geriatrics Society: journal h-index 344 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 1992 — older than 20 years, still counted |
| Sample size | 2 / 4 | 113 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | 4 / 7 | Cited 43 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.2 citations a year over 36 year(s) since 1992 |
| Impact for its field and year | 3 / 6 | Cited 3.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Robert L. Herting: h-index 14 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | New York University: institution h-index 1,612 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 1634705) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 60 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.